Liraglutide

Generic Name: Liraglutide

Brand Names: Saxenda, Victoza, Xultophy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 204656-20-2

Unique Ingredient Identifier: 839I73S42A

Background: Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...

Indication: Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Associated Therapies: Chronic Weight Management therapy

Clinical Trials

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Plerixafor
Drug: Alemtuzumab
Drug: Anakinra
Drug: Etanercept
Drug: Liraglutide

First Posted Date: 2017-06-09

Last Posted Date: 2024-07-19

Lead Sponsor: University of Alberta

Target Recruit Count: 22

Registration Number: NCT03182426

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug: Liraglutide

First Posted Date: 2017-06-01

Last Posted Date: 2022-12-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 720

Registration Number: NCT03172494

Locations: 🇨🇳
Novo Nordisk Investigational Site, Fuzhou, China

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Phase 2

Completed

Conditions: Bipolar Disorder
Obesity

Interventions: Other: Placebo
Drug: LIRAGLUTIDE

First Posted Date: 2017-05-18

Last Posted Date: 2024-03-27

Lead Sponsor: Lindner Center of HOPE

Target Recruit Count: 60

Registration Number: NCT03158805

Locations: 🇺🇸
Lindner Center of HOPE, Mason, Ohio, United States

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3325656
Drug: Placebo
Drug: Liraglutide
Drug: Sitagliptin

First Posted Date: 2017-04-14

Last Posted Date: 2018-08-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT03115099

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇸🇬
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore, Singapore